Recent studies have shown that short-term rapamycin treatment can lead to a variety of metabolic syndromes, such as hyperlipidaemia and insulin resistance, while prolonged treatment can lead to beneficial metabolic changes, including reduced obesity, increased insulin sensitivity, and improved blood lipids 117. Here, INS is linked to obesity disorder.